1. A method for detecting bone metastases in renal cell carcinoma (RCC), which comprises administering to a subject in need thereof an effective amount of I-labeled anti-carbonic anhydrase-IX antibody or antigen-binding fragment thereof and determining the radiation in this subject. The method of claim 1 for detecting bone metastases in clear cell renal cell carcinoma (ccRCC). 3. The method of claim 1 or 2, wherein the subject is a human patient. The method of claim 3, wherein the patient is a preoperative patient. The method of claim 3, wherein the patient is a postoperative patient. The method according to claim 1 or 2, wherein the antibody is a monoclonal antibody G250, especially a chimeric antibody G250 or an antigen-binding fragment thereof. The method of claim 1 or 2, wherein the antibody is administered at a dose of 5 mg to 20 mg, preferably at a dose of about 10 mg. The method according to claim 1 or 2, wherein the activity of the antibody is 15-20 MBq / mg, preferably 18-19 MBq / mg. The method of claim 1 or 2, wherein the measurement comprises positron emission tomography (PET). 10.I-labeled anti-carbonic anhydrase-IX antibody or antigen-binding fragment thereof for use in detecting bone metastases in renal cell carcinoma (RCC) .eleven. An antibody according to claim 10 for use in detecting bone metastases in clear cell renal cell carcinoma (ccRCC). 12. An antibody according to claim 10 or 11, which is a monoclonal antibody G250, in particular a chimeric antibody G250 or an antigen-binding fragment thereof.1. Способ выявления костных метастазов при почечно-клеточной карциноме (RCC), который включает введение нуждающемуся в этом субъекту эффективного количестваI-меченного антитела против карбоангидразы-IX или его антиген-связывающего фрагмента и определение радиации у данного субъекта.2. Способ по п.1 для выявления костных метастазов при светлоклеточной почечно-клеточной карциноме (ccRCC).3. Способ по п.1 или 2, в котором субъектом является пациент-человек
